Board of Directors

The Genea Board comprises a group of very experienced business professionals and doctors with extensive backgrounds in a range of financial and healthcare fields.

The Board is accountable to the Company’s shareholders for its performance.

 

Dr Tomas Stojanov

PhD, GMP(Harvard)

Chief Executive Officer

Tomas was appointed Genea Chief Executive Officer in January 2011 and joined the Genea Board as an executive director at the same time. He is a member of the Science and Research Commercialisation Committee.

With more than 26 years experience in the health, biotechnology and agriculture sectors in a range of capacities, Tomas has conducted scientific research and has worked in operational management and commercialisation roles. Immediately prior to his appointment as CEO of Genea, Tomas was Director of Research and General Manager of Stem Cells and Research.

Dr Robert Woolcott

MBBS(Hons), FRANZCOG, CREI, AMP (Harvard)

Robert joined the Genea Board as a non-executive director in January 2011 and is a member of the Chairman’s Committee.

Medical and Managing Director of Genea Newcastle, Robert has 25 years experience in IVF and reproductive microsurgery. He is a former member of the RANZCOG Reproductive Endocrinology and Infertility subspecialist sub-committee, the Hunter Post Graduate Medical Institute Board and the Mayne Health Medical Advisory Board.

Robert graduated a Bachelor of Medicine/Bachelor of Surgery with honours and also achieved the Advanced Management Program at Harvard.